Cytometry Part B: Clinical Cytometry最新文献

{"title":"Flow cytometric PD-L1 expression enhances identification of Reed-Sternberg cells in suspected Hodgkin lymphoma from lymph node biopsies.","authors":"S Bellesi, G Schiaffini, E Maiolo, C Iacovelli, F Fatone, N Messina, A Bakacs, F D'Alò, S Hohaus","doi":"10.1002/cyto.b.70045","DOIUrl":"https://doi.org/10.1002/cyto.b.70045","url":null,"abstract":"","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148197695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":"110 3","pages":"137-144"},"PeriodicalIF":2.7,"publicationDate":"2026-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148095688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":"110 3","pages":"145-148"},"PeriodicalIF":2.7,"publicationDate":"2026-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148095687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating monocyte partitioning and its alteration in hematological chronic neoplasms.","authors":"Sihem Tarfi, Dorothée Selimoglu-Buet, Ivan Sloma, Orianne Wagner-Ballon","doi":"10.1002/cyto.b.70041","DOIUrl":"https://doi.org/10.1002/cyto.b.70041","url":null,"abstract":"<p><p>Circulating monocyte partitioning refers to the relative quantification of the three main monocyte subsets in the peripheral blood, namely classical (cMo), intermediate (iMo), and non-classical (ncMo) monocytes, as assessed by flow cytometry, a new nomenclature described 15 years ago. This distribution is influenced by physiological variation as well as by certain therapeutic interventions. In addition, pathological alterations in monocyte partitioning are now well characterized in chronic hematological neoplasms. Most notably, a relative accumulation of cMo exceeding 94% of total circulating monocytes was identified more than a decade ago as a phenotypic hallmark of chronic myelomonocytic leukemia (CMML) and has since been incorporated into the most recent revision of the WHO classification. Altered monocyte partitioning has also been reported in patients with myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs), highlighting its broader relevance across myeloid disorders.</p>","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148005093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic performance of flow cytometric osmotic fragility testing in hereditary spherocytosis.","authors":"Silvia Escribano Serrat, Patricia Molina, Pilar Gómez, Mireia Garre, Meritxell Nomdedeu, Blanca De Moner, Estefanía García, Ana Belén Moreno-Castaño, Álex Ramos, Julia Martinez-Sanchez, Marc Pino, Ginés Escolar, Maribel Díaz-Ricart","doi":"10.1002/cyto.b.70040","DOIUrl":"https://doi.org/10.1002/cyto.b.70040","url":null,"abstract":"<p><p>Hereditary spherocytosis (HS) is the most common congenital red blood cell membrane disorder, characterized by structural protein defects that lead to hemolytic anemia. Although several diagnostic tests exist, including osmotic fragility tests (OFTs), acidified glycerol lysis test (AGLT), and the EMA-binding test (EMA), each presents specific limitations regarding sensitivity, specificity, or technical requirements. Flow cytometric osmotic fragility testing (OFT-FCM) emerges as a promising complementary assay, offering a standardized workflow and rapid turnaround time. We conducted a retrospective study including 106 subjects (20 HS patients and 86 healthy controls) recruited at Hospital Clínic de Barcelona between September 2024 and September 2025. Clinical and laboratory data were collected, and all participants underwent OFT, AGLT, EMA, and OFT-FCM using two acquisition protocols (300 and 214 s). Logistic regression and receiver operating characteristic curve analysis were performed to evaluate diagnostic performance and determine optimal cut-off values. HS patients exhibited significantly altered hematologic parameters compared with controls, including higher reticulocyte counts, red cell distribution width, and mean corpuscular hemoglobin. The EMA-binding test demonstrated high specificity (100%) but lower sensitivity (57.9%). OFT achieved high sensitivity (>97%) but low specificity (<47%). AGLT showed balanced accuracy (sensitivity 68.4%, specificity 96.1%). OFT-FCM yielded areas under the curve of 0.85 for both protocols, with optimal thresholds providing specificities of 95-100% and sensitivities of 57-59%. No significant differences were observed between OFT-FCM and EMA performance. OFT-FCM effectively discriminates HS patients from healthy controls and showed diagnostic performance comparable to EMA and favorable relative to classical OFT and AGLT in this cohort, while offering practical advantages in terms of workflow simplicity and turnaround time, and supporting its use as a complementary flow-cytometric assay within the diagnostic work-up of HS.</p>","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147927326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishment of pediatric reference ranges for circulating naïve and memory T and B cell subsets guided by the human immunophenotyping consortium standardization initiative: A large, single center U.S. experience.","authors":"Aaruni Khanolkar, Aisha Ahmed","doi":"10.1002/cyto.b.70039","DOIUrl":"10.1002/cyto.b.70039","url":null,"abstract":"<p><p>Our knowledge of the immune system continues to expand at a rapid pace, and this coupled with technological advances now enables us to interrogate both the breadth and the depth of the immune response at levels without precedent. This has also facilitated rapidly integrating some of this carefully vetted knowledge into clinical practice. Notable examples of these advances include successfully harnessing the therapeutic potential of the immune system (immunotherapy), as well as an expanding menu of clinical flow-cytometry laboratory tests to assess the phenotype and function of the cellular immune response. This has also given rise to an emerging sub-discipline called \"Immune-Health\", with its premise undergirded by the notion that the surveillance capacity and sentinel nature of the immune response might enable the immune system to serve as a reliable barometer of overall health of the individual. At its core, immune-health entails defining baseline immune characteristics for each individual so that perturbations in this baseline signature can serve as clinically actionable biomarkers that might predict the onset, help monitor the progression and potentially mitigate the effects of the underlying disease process. Defining appropriate reference-ranges (RR) for key cellular immune parameters constitutes one of the essential building-blocks of the concept of immune-health. Establishing pediatric RR for cellular correlates of immune-health and disease is a time-consuming and labor-intensive process, and consequently only a select few specialty laboratories at some children's hospitals (with a well-established immunodeficiency/immunedysregulation clinical service) and a couple of large national reference laboratories in the United States (US) have invested their time and effort into this endeavor. Furthermore, the lack of standardization in the definition of immune subsets has also complicated this effort. In 2012, the Human Immunophenotyping Consortium (HIPC) established by the National Institute of Allergy and Infectious Diseases (NIAID)-Division of Allergy, Immunology and Transplantation, published a benchmark study that attempted to standardize the definitions for several cellular immune parameters. In general, Europe has led the charge in advancing these standardization efforts, while similar efforts in the US have been rather sparse, and currently there's a marked paucity of US based studies describing the establishment of pediatric reference ranges (RR) for T and B cell subsets based on the HIPC standardization initiative. In this report, we describe the results of the endeavor, at a large, free-standing children's hospital in the US with a busy clinical immunology service, to establish pediatric reference ranges for naïve and memory T and B cell subsets largely adapted from the subset definitions outlined by the HIPC.</p>","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147873553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic workflow for X-linked agammaglobulinemia integrating BTK expression and B-cell maturation analysis by flow cytometry.","authors":"Mariia Igonina, Ekaterina Malakhova, Mariia Fadeeva, Viktoriia Vedmedskaia, Yuri Shlyapnikov, Elvira Musaeva, Amina Kieva, Elena Raykina, Oyuna Lodoeva, Tatiana Sozonova, Irina Abramova, Daria Yukhacheva, Anna Roppelt, Daria Fomina, Natalia Zinoveva, Anna Mukhina, Aleksey Merkushov, Yulia Rodina, Michael Maschan, Anna Shcherbina, Dmitry Pershin","doi":"10.1002/cyto.b.70038","DOIUrl":"10.1002/cyto.b.70038","url":null,"abstract":"<p><p>X-linked agammaglobulinemia (XLA) is most often caused by impaired Bruton's tyrosine kinase (BTK) function. Rapid laboratory support is needed when genetic findings are inconclusive or pending. We developed a flow-cytometric assay to quantify intracellular BTK protein in monocytes, aiding the diagnosis of XLA. A stain index (SI) reference range was established using healthy donors (n = 25; SI median 1.14, range 1.01-1.66). ROC analysis defined a diagnostic cutoff of SI = 1.79, providing 95% sensitivity and 100% specificity compared to patients with pathogenic BTK variants (n = 40). Using this cutoff, abnormal BTK expression was detected in 38/40 genetically confirmed XLA patients. All patients with variants of uncertain/likely pathogenic significance (n = 17) had SI values above the cutoff. Bone marrow analysis in a patient subset showed a developmental arrest at the Pre-BI stage. The assay offers a rapid, clinically applicable readout to support XLA diagnosis and carrier evaluation in females, effectively complementing genetic testing.</p>","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147873631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Central nervous system involvement in multiple myeloma as a first manifestation of relapse and potential diagnostic pitfall.","authors":"Jessy Ranaivomanana, Léa Ryffel, Muriel Newinger, Amira Mejri, Mario Ojeda-Uribe, Pierre De Marini, Bernard Drénou, Magali Le Garff-Tavernier, Thomas Lefebvre, Agathe Debliquis","doi":"10.1002/cyto.b.70035","DOIUrl":"https://doi.org/10.1002/cyto.b.70035","url":null,"abstract":"<p><p>Central nervous system involvement in multiple myeloma (CNS-MM) is a rare complication usually observed in advanced relapse or refractory settings. The detection of malignant plasma cells in the cerebrospinal fluid (CSF) on the basis of morphology and flow cytometry (FCM) confirms this extra-medullary lesion. The records of 459 MM patients treated between 2016 and 2025 were reviewed, identifying four cases with CSF involvement. CSF and bone marrow samples were processed and analyzed on the basis of morphology and FCM using a dedicated 9-color panel to detect malignant plasma cells. Interleukin-6 (IL-6) and interleukin-10 (IL-10) concentrations were also measured in the CSF using Cytometric Bead Assay. Three patients were in complete remission when CSF analysis revealed CNS-MM. Two patients presented no cerebral lesions, although spinal cord compression was observed for one of them. Two patients presented interference in FCM analysis, supporting the penetration of daratumumab into the CSF. Interleukin measures in the CSF showed low or undetectable IL-10 levels but elevated IL-6 concentrations in some cases. Overall prognosis was poor, with the death of three patients and only one remaining alive at 2 years. CNS-MM could be the first sign of relapse among patients previously in complete remission. It should be envisaged in the case of any myeloma patient with unexplained neurological symptoms, even when imaging is negative. Flow-cytometry panels need to be optimized for plasma-cell detection, especially among patients treated with anti-CD38 antibodies. Identifying patients at risk remains crucial, but prognostic biomarkers such as IL-6 still require validation.</p>","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute myeloid leukemia with mast cell differentiation evolving into mast cell leukemia.","authors":"Liangli Wang, Jie Xu, Lianqun Qiu, Beenu Thakral, Wei Wang, L Jeffrey Medeiros, Hussein A Abbas, Sa A Wang","doi":"10.1002/cyto.b.70036","DOIUrl":"https://doi.org/10.1002/cyto.b.70036","url":null,"abstract":"","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunophenotypic, cytogenetic, and mutational features of chronic lymphocytic leukemia/small lymphocytic lymphoma with atypical immunophenotype.","authors":"Wei J Wang, Sa A Wang, Hong Fang, Qing Wei, Jeffrey L Jorgensen, Shimin Hu, Jie Xu, Shaoying Li, Guilin Tang, Zhenya Tang, L Jeffrey Medeiros, Wei Wang","doi":"10.1002/cyto.b.22248","DOIUrl":"10.1002/cyto.b.22248","url":null,"abstract":"<p><p>Flow cytometric analysis plays an important role in the diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Most CLL cases show a typical immunophenotype characterized by the expression of CD5, CD23, CD43, ROR1, and CD200, along with dim expression of B-cell markers. However, some show an atypical immunophenotype. The immunophenotypic, cytogenetic, and mutational profiles of atypical CLL are not well characterized. In this study, we aim to address these gaps by analyzing a cohort of 270 CLL cases with a focus on those with atypical immunophenotypes. Their detailed immunophenotype as assessed by flow cytometry is presented along with cytogenetics and mutational data. Fifty-three (19.6%) cases exhibited an atypical immunophenotype. The common atypical immunophenotypic features detected included increased CD20 in 17 (32.1%), negative CD43 in 17 (32.1%), negative ROR1 in 16 (30.1%), and increased surface light chain in 11 (20.8%) cases. Trisomy 12 was more frequently detected in atypical versus typical CLL cases (58.5% vs. 20.7%, p < 0.01), including those with decreased to negative expression of CD5, CD23, CD43, and ROR1, and increased expression of CD20 and CD22. Cases with increased CD20 expression more often had mutated IGHV. BIRC3 is the most frequent mutation in the atypical CLL group, and alterations in BIRC3 (p = 0.02), KRAS (p = 0.03), NRAS (p < 0.01), KMT2D (p < 0.01), and SMARCA4 (p = 0.02) were more frequently detected in atypical CLL when compared to typical CLL. In summary, approximately 20% of CLL cases show an atypical immunophenotype, and these cases have cytogenetic abnormalities and mutation profiles that differ in frequency from typical CLL cases. Recognition of the immunophenotype of atypical CLL can be helpful in the diagnosis and differential diagnosis in low-grade B-cell neoplasms.</p>","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":" ","pages":"160-171"},"PeriodicalIF":2.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144854837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}